Policing harm reduction: A case study of who counts as human.  Snyder SN, Voronka J, Guta A, Pilling MD.  Crime Media Cult. 2024 Dec 29;22(1):20-44. doi: 10.1177/17416590241305027. PMID: 41446705; PMCID: PMC12725242. https://pmc.ncbi.nl…

Drogennotfallprophylaxe - Neue Entwicklungen zu Take- Home-Naloxon Dirk Schäffer (Diese E-Mail-Adresse ist vor Spambots geschützt! Zur Anzeige muss JavaScript eingeschaltet sein.) und Simon Fleißner (Diese E-Mail-Adresse ist vor Spambots geschützt…

Effectiveness, acceptability, and feasibility of naloxone in carceral settings: a scoping review.  Ravichandran N, Cullen W, Van Hout MC, Smyth J, Crowley D.  Harm Reduct J. 2025 Nov 29. doi: 10.1186/s12954-025-01358-x. Epub ahead of pri…

Post-marketing Surveillance of Intranasal Nalmefene: Prevalence and Clinical Relevance of Precipitated Withdrawal.  Paavola J, Skolnick P, Wheeler A, Mankabady B, Laffont CM, Heidbreder C.  Cureus. 2025 Oct 22;17(10):e95174. doi: 10.7759…

Combining the alpha-2 adrenergic agonist clonidine with naloxone rescues fentanyl-induced physiologic dysfunction and increases survival.  Rivera A, Schutzer WE, Sonneborn A, Shotwell SL, Janowsky A, Abbas AI, Torralva R.  bioRxiv [Prepr…

Is Fentanyl Rebound an Intrinsic Feature of Naloxone Reversal?  Voronkov M, Nikonov G, Uzbil M, Milevich G, Abernethy J, Barthélémy I.  Pharmaceuticals (Basel). 2025 Oct 29;18(11):1634. doi: 10.3390/ph18111634. PMID: 41304879; PMCID: PMC…